Novel therapeutics under development for TTP include nanobodies directed against domain A1 of vWF (caplacizumab), recombinant ADAMTS13, plasma cell inhibitors (bortezomib), N-acetylcysteine, and VWF-glycoprotein Ib/IX interaction inhibitors (anfibatide) [18]. Here, ADAMTS13 is linked to thrombotic thrombocytopenic purpura.